The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Effects of Resveratrol on Polycystic Ovary Syndrome: A Double-blind, Randomized, Placebo-controlled Trial
Abstract
CONTEXT: Polycystic ovary syndrome (PCOS) is the most common endocrinopathy affecting women of reproductive age. Hyperandrogenism is the central feature of PCOS. Studies on isolated ovarian theca-interstitial cells suggest that resveratrol, a natural polyphenol, reduces androgen production. OBJECTIVE: This study was designed to evaluate endocrine and metabolic effects of resveratrol on PCOS. DESIGN AND SETTING: This was a randomized (1:1) double-blind, placebo-controlled trial that evaluated the effects of resveratrol over a period of 3 months in an academic hospital. PATIENTS AND OTHER PARTICIPANTS: Subjects with PCOS were identified according to the Rotterdam criteria. Thirty-four subjects were enrolled and 30 subjects completed the trial. Evaluations were performed at baseline and repeated after 3 months of treatment. INTERVENTION: Resveratrol (1,500 mg p.o.) or placebo were administered daily. MAIN OUTCOME MEASURE: Primary outcome was the change in the serum total T. RESULTS: Resveratrol treatment led to a significant decrease of total T by 23.1% (P = .01). In parallel, resveratrol induced a 22.2% decrease of dehydroepiandrosterone sulfate (P = .01), a decrease of fasting insulin level by 31.8% (P = .007) and an increase of the Insulin Sensitivity Index (Matsuda and DeFronzo) by 66.3% (P = .04). Levels of gonadotropins, the lipid profile as well as markers of inflammation and endothelial function were not significantly altered. CONCLUSIONS: Resveratrol significantly reduced ovarian and adrenal androgens. This effect may be, at least in part, related to an improvement of insulin sensitivity and a decline of insulin level.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a randomized placebo-controlled trial, treatment with 1500 mg daily of resveratrol significantly decreased testosterone and dehydroepiandrosterone sulfate excess by ~23% in PCOS women over a period of 3 months [138].”
From Mediterranean diet nutrients to turn the tide against insulin resistance and related diseases (2020) · cites this paper as [138]
Citations
Cites
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
Katz, A., Nambi, S. S., Mather, K., Baron, A. D., Follmann, D. A., Sullivan, G., & Quon, M. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6661 · Cited by 3,931 · cited 1×
“Evaluation of insulin sensitivity using fasting measures used the method described by Katz et al (22): Quantitative Insulin Sensitivity Check Index (QUICKI) 1/[log(fasting insulin) log (fasting glucose)].”
MethodInsulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis
Dunaif, A. E. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.6.0318 · Cited by 2,776
The Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected Population
Azziz, R., Woods, K. S., Reyna, R., Key, T. J., Knochenhauer, E. S., & Yıldız, B. O. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032046 · Cited by 2,715
March, W. A., Moore, V. M., Willson, K. J., Phillips, D. I. W., Norman, R. J., & Davies, M. J. (2010) · Human Reproduction · doi:10.1093/humrep/dep399 · Cited by 1,799
Asunción, M., Calvo, R. M., Millán, J. L. S., Sancho, J., Ávila, S., & Escobar-Morreale, H. F. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6682 · Cited by 1,328
Diamanti‐Kandarakis, E., Kouli, C., Bergiele, A. T., Filandra, F. A., Tsianateli, T. C., Spina, G., Zapanti, E. D., & Bartzis, M. I. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.11.6148 · Cited by 1,107
Wild, R. A., Carmina, E., Diamanti-Kandarakis, E., Dokras, A., Escobar-Morreale, H. F., Futterweit, W., Lobo, R., Norman, R. J., Talbott, E., & Dumesic, D. A. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2724 · Cited by 1,010
Nelson, V. L., Legro, R. S., Strauss, J. F., & McAllister, J. M. (1999) · Molecular Endocrinology · doi:10.1210/mend.13.6.0311 · Cited by 556
Cited by
Sorted by citations
Health benefits of resveratrol: Evidence from clinical studies
Singh, A. P., Singh, R., Verma, S. S., Rai, V., Kaschula, C. H., Maiti, P., & Gupta, S. C. (2019) · Medicinal Research Reviews · doi:10.1002/med.21565 · Cited by 523
Tatone, C., Emidio, G. D., Barbonetti, A., Carta, G., Luciano, A. M., Falone, S., & Amicarelli, F. (2018) · Human Reproduction Update · doi:10.1093/humupd/dmy003 · Cited by 296
Mediterranean diet nutrients to turn the tide against insulin resistance and related diseases
Mirabelli, M., Chiefari, E., Arcidiacono, B., Corigliano, D. M., Brunetti, F. S., Maggisano, V., Russo, D., Foti, D. P., & Brunetti, A. (2020) · Nutrients · doi:10.3390/nu12041066 · Cited by 272
“In a randomized placebo-controlled trial, treatment with 1500 mg daily of resveratrol significantly decreased testosterone and dehydroepiandrosterone sulfate excess by ~23% in PCOS women over a period of 3 months [138].”
BackgroundMethodInfluentialAdvances in phytochemical delivery systems for improved anticancer activity
Lagoa, R., Silva, J. S., Rodrigues, J. R., & Bishayee, A. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.04.004 · Cited by 215
Brown, K., Theofanous, D., Britton, R. G., Aburido, G., Pepper, C., Undru, S. S., & Howells, L. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020747 · Cited by 209
Metadata
- Authors
- Banaszewska, B., Wrotyńska-Barczyńska, J., Spaczynski, R. Z., Pawelczyk, L., & Duleba, A. J.
- Affiliations
- Poznan University of Medical Sciences (PL)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2016-11
- Volume
- 101
- Issue
- 11
- Pages
- 4322-4328
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2532986090
- Cited by
- 173
- References
- 35
- Citations by year
- 2026: 21 · 2025: 14 · 2024: 22 · 2023: 23 · 2022: 23 · 2021: 24 · 2020: 16 · 2019: 17 · 2018: 7 · 2017: 6
- FWCI
- 13.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
- Keywords
- resveratrol, polycystic ovary syndrome, hyperandrogenism, serum total testosterone, dehydroepiandrosterone sulfate, insulin sensitivity, fasting insulin, insulin resistance, insulin-like growth factor I, ovarian androgen production, adrenal androgens, lipid profile, inflammation, endothelial function
- MeSH terms
- Resveratrol, Adult, Antioxidants, Double-Blind Method, Female, Humans, Insulin, Insulin Resistance, Polycystic Ovary Syndrome, Stilbenes, Testosterone, Outcome Assessment, Health Care, Dehydroepiandrosterone Sulfate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
